Zika virus vaccine

Source: Wikipedia, the free encyclopedia.

A

Guillain-Barré syndrome, a potential consequence of Zika virus infection. Additionally, as dengue virus is closely related to Zika virus, the vaccine needs to minimize the possibility of antibody-dependent enhancement of dengue virus infection.[5][6][7][8]

DNA vaccine

A vial of a DNA vaccine for Zika virus submitted for testing

As of March 31, 2017 a

platform used to develop a West Nile virus vaccine, the DNA vaccine is designed to assemble protein particles that mimic Zika virus and trigger the body's immune response.[citation needed
]

Purified inactivated vaccine (ZPIV)

A purified inactivated vaccine is currently under development by the Walter Reed Army Institute of Research.[11][12] This vaccine is based on the same technology used to develop a vaccine against Japanese Encephalitis Virus. As the ZPIV vaccine contains inactivated Zika particles, the virus cannot replicate and cause disease in humans. U.S. Army researchers agreed to give Sanofi permission to develop the technology, but protest in Congress halted the venture. Initial results at Beth Israel Deaconess Medical Center and at other hospitals involved in the early clinical trials were considered to be promising.[13][14]

Live attenuated vaccine

A live attenuated vaccine, in which the virus is genetically altered as to not cause disease in humans, is undergoing phase 1 clinical trials. This vaccine is based on the dengue vaccine Dengvaxia, which has been approved for use in humans.[15]

mRNA vaccine

A modified

Moderna Therapeutics containing the E and PrM proteins is undergoing concurrent phase 1 and 2 clinical trials.[16][17]

Viral vector-based vaccines

Multiple vaccines are also being developed using safe, non-pathogenic, viruses as vectors for immunogenic Zika virus proteins. One phase 1 trial is using the

Adenovirus as a vector and phase 1 studies will be complete in 2019.[19] Adenoviruses have been previously used as a vaccine platform for HIV and elicit a strong immune response.[20] A chimeric Binjari-Zika vaccine is highly effective for immunization in mice.[21]

References

  1. ^ "Zika virus vaccine product development". World Health Organization. Archived from the original on July 19, 2016.
  2. PMID 29921914
    .
  3. PMID 28432975
    .
  4. ^ "Zika Virus Vaccines | NIH: National Institute of Allergy and Infectious Diseases". www.niaid.nih.gov.
  5. PMID 28228277
    .
  6. PMID 28878742
    .
  7. PMID 28487557
    .
  8. PMID 30469444
    .
  9. ^ "Phase 2 Zika Vaccine Trial Begins in U.S., Central and South America | NIH: National Institute of Allergy and Infectious Diseases". www.niaid.nih.gov.
  10. PMID 27708058
    .
  11. ^ "Testing of Investigational Inactivated Zika Vaccine in Humans Begins | NIH: National Institute of Allergy and Infectious Diseases". www.niaid.nih.gov.
  12. PMID 32194996
    .
  13. ^ Reuters. Steenhuysen, Julie and Chang, Richard. (4 December 2017). "Trial results of Zika vaccine Sanofi dropped show promise". WIBQ website Archived 2019-06-17 at the Wayback Machine Retrieved 13 December 2017.
  14. ^ Modjarrad, Kayvon; Lin, Leyi; George, Sarah L.; et al. (4 December 2017). "Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomized, double-blind, placebo-controlled clinical trials." The Lancet DOI: https://dx.doi.org/10.1016/S0140-6736(17)33106-9 | Retrieved 14 December 2017.
  15. ^ "Zika Virus Vaccines | NIH: National Institute of Allergy and Infectious Diseases". www.niaid.nih.gov.
  16. ^ "Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects - Full Text View - ClinicalTrials.gov". 6 December 2019.
  17. PMID 28432975
    .
  18. ^ "Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability - Full Text View - ClinicalTrials.gov". 21 June 2021.
  19. ^ "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers". Retrieved 25 July 2018.
  20. PMID 26833336.{{cite journal}}: CS1 maint: numeric names: authors list (link
    )
  21. PMID 35062746
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Zika_virus_vaccine&oldid=1167158899"